Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2000-01-28
2002-09-10
Caputa, Anthony C. (Department: 1642)
Chemistry: molecular biology and microbiology
Vector, per se
C435S252300, C435S325000, C435S366000, C536S023100, C536S023500, C536S024500
Reexamination Certificate
active
06448073
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to antigens associated with cancer, the nucleic acid molecules encoding them, as well as the uses of these.
BACKGROUND AND PRIOR ART
It is fairly well established that many pathological conditions, such as infections, cancer, autoimmune disorders, etc., are characterized by the inappropriate expression of certain molecules. These molecules thus serve as “markers” for a particular pathological or abnormal condition. Apart from their use as diagnostic “targets”, i.e., materials to be identified to diagnose these abnormal conditions, the molecules serve as reagents which can be used to generate diagnostic and/or therapeutic agents. A by no means limiting example of this is the use of cancer markers to produce antibodies specific to a particular marker. Yet another non-limiting example is the use of a peptide which complexes with an MHC molecule, to generate cytolytic T cells against abnormal cells.
Preparation of such materials, of course, presupposes a source of the reagents used to generate these. Purification from cells is one laborious, far from sure method of doing so. Another preferred method is the isolation of nucleic acid molecules which encode a particular marker, followed by the use of the isolated encoding molecule to express the desired molecule.
Two basic strategies have been employed for the detection of such antigens, in e.g., human tumors. These will be referred to as the genetic approach and the biochemical approach. The genetic approach is exemplified by, e.g., dePlaen et al., Proc. Natl. Sci. USA 85: 2275 (1988), incorporated by reference. In this approach, several hundred pools of plasmids of a cDNA library obtained from a tumor are transfected into recipient cells, such as COS cells, or into antigen-negative variants of tumor cell lines which are tested for the expression of the specific antigen. The biochemical approach, exemplified by, e.g., O. Mandelboim, et al., Nature 369: 69 (1994) incorporated by reference, is based on acidic elution of peptides which have bound to MHC-class I molecules of tumor cells, followed by reversed-phase high performance liquid chromography (HPLC). Antigenic peptides are identified after they bind to empty MHC-class I molecules of mutant cell lines, defective in antigen processing, and induce specific reactions with cytotoxic T-lymphocytes. These reactions include induction of CTL proliferation, TNF release, and lysis of target cells, measurable in an MTT assay, or a
51
Cr release assay.
These two approaches to the molecular definition of antigens have the following disadvantages: first, they are enormously cumbersome, time-consuming and expensive; and second, they depend on the establishment of cytotoxic T cell lines (CTLs) with predefined specificity.
The problems inherent to the two known approaches for the identification and molecular definition of antigens is best demonstrated by the fact that both methods have, so far, succeeded in defining only very few new antigens in human tumors. See, e.g., van der Bruggen et al., Science 254: 1643-1647 (1991); Brichard et al., J. Exp. Med. 178: 489-495 (1993); Coulie, et al., J. Exp. Med. 180: 35-42 (1994); Kawakami, et al., Proc. Natl. Acad. Sci. USA 91: 3515-3519 (1994).
Further, the methodologies described rely on the availability of established, permanent cell lines of the cancer type under consideration. It is very difficult to establish cell lines from certain cancer types, as is shown by, e.g., Oettgen, et al., Immunol. Allerg. Clin. North. Am. 10: 607-637 (1990). It is also known that some epithelial cell type cancers are poorly susceptible to CTLs in vitro, precluding routine analysis. These problems have stimulated the art to develop additional methodologies for identifying cancer associated antigens.
One key methodology is described by Sahin, et al., Proc. Natl. Acad. Sci. USA 92: 11810-11913 (1995), incorporated by reference. Also, see U.S. Pat. No. 5,698,396, and Application Ser. No. 08/479,328, filed on Jun. 7, 1995 and Jan. 3, 1996, respectively. All three of these references are incorporated by reference. To summarize, the method involves the expression of cDNA libraries in a prokaryotic host. (The libraries are secured from a tumor sample). The expressed libraries are then immunoscreened with absorbed and diluted sera, in order to detect those antigens which elicit high titer humoral responses. This methodology is known as the SEREX method (“Serological identification of antigens by Recombinant Expression Cloning”). The methodology has been employed to confirm expression of previously identified tumor associated antigens, as well as to detect new ones. See the above referenced patent applications and Sahin, et al., supra, as well as Crew, et al., EMBO J 144: 2333-2340 (1995).
This methodology has been applied to a range of tumor types, including those described by Sahin et al., supra, and Pfreundschuh, supra, as well as to esophageal cancer (Chen et al., Proc. Natl. Acad. Sci. USA 94: 1914-1918 (1997)); lung cancer (Gure et al., Cancer Res. 58: 1034-1041 (1998)); colon cancer (Serial No. 08/948,705 filed Oct.
10, 1997)
incorporated by reference, and so forth. Among the antigens identified via SEREX are the SSX2 molecule (Sahin et al., Proc. Natl. Acad. Sci. USA 92: 11810-11813 (1995); Tureci et al., Cancer Res. 56: 4766-4772 (1996); NY-ESO-
1
Chen, et al., Proc. Natl. Acad. Sci. USA 94: 1914-1918 (1997); and SCP1 (Ser. No. 08/892,705 filed Jul. 15, 1997) incorporated by reference. Analysis of SEREX identified antigens has shown overlap between SEREX defined and CTL defined antigens. MAGE-1, tyrosinase, and NY-ESO-1 have all been shown to be recognized by patient antibodies as well as CTLs, showing that humoral and cell mediated responses do act in concert.
It is clear from this summary that identification of relevant antigens via SEREX is a desirable aim. In U.S. patent application Ser. No. 09/451,739, filed Nov. 30, 1999 and incorporated by reference, various antigens have been identified, and nucleic acid molecules encoding these have been isolated. The inventors have applied the methodologies described supra and have identified several new antigens associated with cancer, as detailed in the description which follows.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
REFERENCES:
patent: WO9818942 (1998-05-01), None
Pfreundschuh, M., “Exploitation of the B cell repertoire for the identification of human tumor antigens”, Cancer Chemother Pharmacol, 2000, vol. 46, suppl., pp. S3-S7.*
Obata et al., “SEREX analysis of gastric cancer antigens”, Cancer Chemother Pharmacol, 2000, vol. 26, suppl., pp. S37-S42.*
Bowie et al “Deciphering the Message in protein Sequences:Tolerance to Amino Acid substitutions” Science, vol. 247, pp. 1306-1310, 1990.*
Lazar et al, “Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47 and Leuine 48 Results in Different Biological Activities”, Molecular and Cellular Biology, vol. 8, pp. 1247-1252, 1988.*
Burgess et al “Possible Dissociation of the Heparin-binding and Mitogenic Acitivies of Heparin-binding Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a single Lysine Residue”, Journal of Cellular biology, vol. 111, pp 1990.*
P. Bork, “Powers and pitfalls in sequence analysis”, Genome Research, vol. 10, pp. 398-400, 2000.*
Paul, W.E., ed., Fundamental Immunology (Textbook), 3rd edition, pp. 249-251, 1993.*
Klein, J. “Self-nonself discrimination, histoincompatability, and the concept of immunology” Immunogenetics, vol. 50, pp. 116-123, 1999.*
Ristori et al “Compostional bias and mimicry toward the nonself proteome in immunodominat T cell epitopes of sel and nonself” FASEB Journal, vol. 14, pp. 431-438, 2000.*
Alberts et al, Ed., Molecular Biology of the Cell (textbook) 3rd edition, p. 465, 1994.*
Shantz and Pegg, “Translational regulation of ornithine decarboxylase and other enzymes”, International J of Biochemistry and Cell Biology, vol. 31, pp. 107-122, 1999.*
McClean and Hill, “Evidence of post-translational regulation of p-glycoprotein”, European J.
Chen Yao-tseng
Gure Ali
Jager Dirk
Jager Elke
Knuth Alexander
Canella Karen A.
Caputa Anthony C.
Fulbright & Jaworski LLP.
Ludwig Institute for Cancer Research
LandOfFree
Isolated nucleic acid molecules encoding cancer associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated nucleic acid molecules encoding cancer associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated nucleic acid molecules encoding cancer associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2831996